Paroxysmal Cold Hemoglobinuria Treatments
Find Paroxysmal Cold Hemoglobinuria Treatments
Medications for Paroxysmal Cold Hemoglobinuria
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Paroxysmal Cold Hemoglobinuria.
Found 6 Approved Drugs for Paroxysmal Cold Hemoglobinuria
Eculizumab
Brand Names
Soliris, BKEMV, Epysqli
Eculizumab
Brand Names
Soliris, BKEMV, Epysqli
Form: Injection
Method of administration: Intravenous
FDA approval date: April 02, 2007
Classification: Complement Inhibitor
EPYSQLI is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
Ultomiris
Generic Name
Ravulizumab
Ultomiris
Generic Name
Ravulizumab
Form: Solution
Method of administration: Intravenous
FDA approval date: December 21, 2018
Classification: Complement Inhibitor
ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
Pegcetacoplan
Brand Names
Empaveli, Syfovre
Pegcetacoplan
Brand Names
Empaveli, Syfovre
Form: Injection
Method of administration: Subcutaneous, Intravitreal
FDA approval date: May 14, 2021
Classification: Complement Inhibitor
EMPAVELI is a complement inhibitor indicated: for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Fabhalta
Generic Name
Iptacopan
Fabhalta
Generic Name
Iptacopan
Form: Capsule
Method of administration: Oral
FDA approval date: December 05, 2023
Classification: Complement Factor B Inhibitor
FABHALTA is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). FABHALTA is a complement factor B inhibitor, indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). ( 1 )
Voydeya
Generic Name
Danicopan
Voydeya
Generic Name
Danicopan
Form: Tablet, Kit
Method of administration: Oral
FDA approval date: March 29, 2024
VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). VOYDEYA is a complement factor D inhibitor indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) ( 1 ). Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab. Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab.
Showing 1-5 of 6
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances